Sartorius AG · XETR:SRT

Sartorius — Merger or Acquisition (April 2023)

10 slides from Sartorius's merger presentation, Apr 5, 2023

  1. Slide 1: Conference Call Acquisition of Polyplus

    Conference Call Acquisition of Polyplus Joachim Kreuzburg, René Fáber, Rainer Lehmann Sartorius | Sartorius Stedim Biotech | April 5, 2023

  2. Slide 2: Polyplus at a glance

    Polyplus at a glance HQ in Strasbourg, France; Portfolio Locations in Belgium, U.S., and China  Transfection as well as other DNA/RNA delivery reagents  Plasmid DNA in high quality and GMP grade ~270 employees  Key applications include production of viral vectors used in cell and gene therapies G

  3. Slide 3: Robust innovations for each stage of the workflow

    Robust innovations for each stage of the workflow Plasmids Transfection Other reagents PEI Pro FectoVIR LNP production Plasmid design Applications Plasmid production Virus production In-vivo RNA & DNA delivery Genome editing Integrated plasmid Transfection reagent Transfection reagent Novel reagents

  4. Slide 4: Transfection reagents and plasmids are critical raw materials for the production of viral vectors

    Transfection reagents and plasmids are critical raw materials for the production of viral vectors Viral vector upstream process Transfection reagents and plasmids are mission-critical Relevant component Impact on yield 1 2 Optimized plasmid design Plasmid Plasmid design Transfection reagent and qual

  5. Slide 5: Combination of portfolios creates differentiated, fully integrated, and broad workflow solution

    Combination of portfolios creates differentiated, fully integrated, and broad workflow solution to address pain points Polyplus` solutions for Sartorius` media, cell transfection and line and downstream plasmids capabilities Sartorius` solutions for process development and manufacturing

  6. Slide 6: Strengthen positioning in a high-growth segment

    Strengthen positioning in a high-growth segment ~45% of biopharma R&D pipeline is Viral-based and Advanced Therapies Market dynamics based on new modalities1 markets growing particularly fast CAGRs 2022–20262 Advanced  Large and rapidly growing pipeline of Therapies Advanced gene and gene modified

  7. Slide 7: Significant synergy potential

    Significant synergy potential Portfolio Cross selling Global platform  Highly complementary product  Access to customers in advanced  Complementary R&D capabilities portfolio without overlaps therapies across the entire to create innovation  Further enhance relevance of our workflow  Leverage s

  8. Slide 8: Key terms and timeline

    Key terms and timeline  Approx. €2.4bn Purchase price  Bridge loan facility at Sartorius AG level for up to 2 years  Refinancing mainly by long-term debt; depending on market conditions, a smaller portion Financing potentially refinanced through a capital increase at Sartorius Stedim Biotech S.A.

  9. Slide 9: Questions & Answers

    Questions & Answers 9

  10. Slide 10: Disclaimer

    Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha

Sartorius — Merger or Acquisition (April 2023) on 6ix